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Prevalence ofMITF p.E318K in PatientsWithMelanoma
Independent of the Presence of CDKN2A CausativeMutations
Miriam Potrony, MSc; Joan Anton Puig-Butille, PhD; Paula Aguilera, MD; Celia Badenas, PhD;
Gemma Tell-Marti, MSc; Cristina Carrera, MD, PhD; Luis Javier del Pozo, MD; Julian Conejo-Mir, MD;
JosepMalvehy, MD, PhD; Susana Puig, MD, PhD
IMPORTANCE Themain high-penetrancemelanoma susceptibility gene is CDKN2A, encoding
p16INK4A and p14ARF. The geneMITF variant p.E318K also predisposes to melanoma and
renal cell carcinoma. To date, the prevalence ofMITF p.E318K and its clinical and phenotypical
implications has not been previously assessed in a single cohort of Spanish patients with
melanoma or in p16INK4Amutation carriers.
OBJECTIVES To evaluate the prevalence ofMITF p.E318K in Spanish patients with melanoma
and assess the association with clinical and phenotypic features.
DESIGN, SETTING, AND PARTICIPANTS A hospital-based, case-control studywas conducted at
theMelanoma Unit of Hospital Clinic of Barcelona, withMITF p.E318K genotyped in all
patients using TaqMan probes. We included 531 patients: 271 patients with multiple primary
melanoma (MPM) without mutations affecting p16INK4A (wild-type p16INK4A); 191
probands frommelanoma-prone families with a single melanoma diagnosis and without
mutations affecting p16INK4A, and 69 probands from different families carrying CDKN2A
mutations affecting p16INK4A. A population-based series of 499 age- and sex-matched
cancer-free individuals from the Spanish National Bank of DNAwere included as controls.
Patients were recruited between January 1, 1992, and June 30, 2014; data analysis was
conducted from September 1 to November 30, 2014.
MAIN OUTCOMES ANDMEASURES The genetic results of theMITF p.E318K variant were
correlated with clinical and phenotypic features.
RESULTS Among the 531 patients, the prevalence of theMITF p.E318K variant was calculated
among the different subsets of patients included and was 1.9% (9 of 462) in all melanoma
patients with wild-type p16INK4A, 2.6% (7 of 271) in those with MPM, and 2.9% (2 of 69) in
the probands of families with p16INK4Amutations. With results reported as odds ratio (95%
CI), theMITF p.E318K was associated with an increasedmelanoma risk (3.3 [1.43-7.43];
P < .01), especially in MPM (4.5 [1.83-11.01]; P < .01) and high nevi count (>200 nevi) (8.4
[2.14-33.19]; P < .01). Two fast-growingmelanomas were detected among 2MITF p.E318K
carriers during dermatologic digital follow-up.
CONCLUSIONS AND RELEVANCE In addition tomelanoma risk,MITF p.E318K is associated with
a high nevi count and could play a role in fast-growingmelanomas. Testing forMITF p.E318K
should not exclude patients with knownmutations in p16INK4A. Strict dermatologic
surveillance, periodic self-examination, and renal cell carcinoma surveillance should be
encouraged in this context.
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A pproximately8%to12%ofmelanomacasesoccur inafa-milial context.1 Themain high-penetrance gene impli-cated in melanoma susceptibility is CDKN2A (OMIM
code: 600160; GenBank accession number: NM_000077.4
[p16INK4A] and NM_058195.3 [p14ARF]). The gene encodes
2 tumor suppressor proteins: p16INK4A,which promotes cell-
cycle arrest and plays a role in senescence, and p14ARF,which
acts through p53-regulating apoptosis.2,3 Germline CDKN2A
mutationsarefoundin20%to40%ofmelanoma-pronefamilies4
and in8%to 16%ofpatientswithmultipleprimarymelanomas
without other cases in the family.5 Patients with melanoma
carryingCDKN2Amutationshave a younger ageof onset anda
higher number of primary melanomas, and the presence of
CDKN2Amutations is associatedwith dysplastic nevi.4-7
TheMC1Rgene(OMIM:155555;GenBank:NM_002386)con-
trols the pigmentation process and is amoderate-risk gene for
melanoma susceptibility.8,9 Loss of function variants inMC1R
impairs theability toactivate thepigmentationpathwayresult-
ing in the red-hair color (RHC) phenotype. The RHC pheno-
type ischaracterizedbyfairpigmentation(fair skin, redhair,and
freckles) andby sun sensitivity (poor tanning response and so-
lar lentigines).10 These variants increase the risk ofmelanoma
with an odds ratio (OR) between 1.5 and 4.1.8,10,11 The associa-
tion betweenMC1R variants andmelanoma is stronger in indi-
viduals with dark skin or few nevi.12,13 Therefore, there might
be amodest benefit tomeasureMC1R genotype formelanoma
risk prediction, in addition to clinically measured pigmenta-
tion characteristics and nevi count.12 A rare functional variant
inMITF, p.E318K (rs149617956), was identified in 2 indepen-
dent studies.14,15Thisvariantmaybeconsideredasamoderate-
risk allele in melanoma.14-17 The master regulator gene of me-
lanocytedevelopmentanddifferentiation isMITF, and it is also
associatedwithmelanomadevelopmentandprogression.18The
presenceofMITFp.E318Kpredisposes toboth familial andspo-
radic melanoma susceptibility, and/or renal cell carcinoma
(RCC), and/or pancreatic cancer.14-16MITF p.E318K occurs at a
conserved small ubiquitinlikemodifier position, and this vari-
ant decreases the amount of small ubiquitinlike modifier–
modified MITF forms.14 The small ubiquitinlike modifier of
MITF represses its transcriptional activity; therefore, p.E318K
increasesMITFtranscriptionalactivityandmayresult in theup-
regulation of distinct sets of genes. Furthermore, this variant
promotes invasiveandtumorigenicbehaviors inmelanomaand
RCCcellsandmightfavoraphenotypicswitchofmelanomacells
toward a tumor-initiating cell phenotype.14
To our knowledge, the role of the MITF p.E318K has not
been previously explored in Spanish patients with mela-
noma.Theaimof this studywastoevaluate theroleof theMITF
p.E318K variant in Spanish patients with melanoma and as-
sess the association of this variant with clinical and pheno-
typic features.
Methods
Patients
Atotal of 531patients at high riskofmelanoma, recruited from
January 1, 1992, to June30,2014, at theMelanomaUnitofHos-
pital Clinic of Barcelona, were included in the study.
Patients were grouped into 3 different subsets. The first set
was composed of 271 individuals (51%) with multiple pri-
mary melanoma (MPM) (212 sporadic MPM and 59 familial
MPM) who did not carry mutations in CDKN2A affecting the
p16INK4A protein (hereinafter referred to as wild-type
p16INK4A). One patient from this set carried a CDKN2A
mutation affecting p14ARF, and 75 patients were previously
included in the Bertolotto et al14 study. The second set con-
sisted of 191 probands (36%) from melanoma-prone fami-
lies, with at least 2 melanoma cases, with a single mela-
noma diagnosis (all wild-type p16INK4A). The third set
contained 69 probands (13%) from families bearing CDKN2A
mutations affecting p16INK4A, independent of the number
of primary melanomas.
Clinical andphenotypic characteristicswere collected for
mostof the531patients, includingthenumberofprimarymela-
nomas (99%), age of onset (90%), melanoma subtype (76%),
melanoma location (84%), Breslow thickness (74%), eye and
hair color (75%), skinphototype (80%), andnevuscount (72%).
The familial history of pancreatic cancer was obtained from
80%of thepatients, andpersonal historyof other cancerswas
supplied by the patients carrying the variant.
The study was approved by the ethics committee of the
Hospital Clinic of Barcelona, and patients provided written
informed consent. Participants did not receive financial
compensation.
A population-based series of 499 cancer-free individu-
als recruited at the Spanish National Bank of DNA were used
as controls. The controls were sex and age matched with a
group of consecutively recruited individuals with sporadic
melanoma in the Melanoma Unit of Hospital Clinic of Barce-
lona from January 1998 to December 2013. The mean (SD)
age in the control group was 52.2 (18.0) years. Overall, 269
of the 499 patients were women (53.9%) and 230 were men
(46.1%).
MITF p.E318K Genotyping
TheMITFvariantp.E318K(rs149617956)wasanalyzed(Custom
TaqManSNPGenotypingAssays) according tomanufacturer’s
recommendations in all of the patients and the control group.
The process was carried out using polymerase chain reaction
(7900HTFastRealTimePCRSystem;AppliedBiosystems)and
SDS, version 2.4, software (Applied Biosystems).
Statistical Analysis
The prevalence of MITF p.E318K was assessed in all mela-
nomapatientswithwild-typep16INK4Aand theCDKN2Amu-
tation carrier set. In a French cancer-free and Italian control
population, the frequencyofcarrierswas0.6%(14of2205).14,16
The risk conferred by MITF p.E318K to melanoma develop-
ment in the Spanish patients withwild-type p16INK4Amela-
nomawas evaluated by comparing our group of patientswith
the Spanish and previously reported French and Italian con-
trols together since there were no statistically significant dif-
ferences between them. Clinical and phenotypic characteris-
tics were analyzed regarding the presence of the p.E318K
variant in patientswithwild-type p16INK4A. Odds ratios and
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95%CIswerecalculated.The2-sidedFisherexact testwasused
to look for statistical significance in proportion comparison.
Age of onset was tested using an unpaired, 2-tailed t test.
Breslowthicknesswasevaluatedusing theMann-Whitney test.
The resultswere considered statistically significant atP < .05.
Statistical analyses were conducted using SPSS, version 17.0
(SPSS Inc). Data analysis was conducted from September 1 to
November 30, 2014.
Results
CDKN2A gene, coding for the p16INK4A and p14ARF pro-
teins, is ahigh-penetrance susceptibility inmelanoma.There-
fore, we calculated the prevalence of theMITF p.E318K vari-
ant in all 531 patients separated according to p16INK4A status
(wild-typeormutated): 462patientswithwild-typep16INK4A
and 69 patients with mutated p16INK4A. Among these, the
prevalence of theMITFp.E318Kvariantwas 1.9% (9 of 462) in
allmelanomapatientswithwild-typep16INK4A,2.6%(7of271)
in thosewithMPM,and2.9% (2of69) in theprobandsof fami-
liesbearingamutation inp16INK4A.All individualswithMITF
p.E318K carried the variant in heterozygosis. The prevalence
of the variant in a Spanish cancer-free population was 0.4%
(2 of 499), with no statistically significant difference with
French or Italian controls (P = .54).14,16 With results reported
as OR (95% CI), the MITF variant p.E318K increased the risk
of developingmelanoma in all melanoma patients withwild-
typep16INK4A (3.3 [1.43-7.43];P < .01) and in thosewithMPM
(4.5 [1.83-11.01]; P < .01), using the Mediterranean controls
(Table 1).When calculating the ORusing, as a control popula-
tion, the European non-Finnish population from the ExAC/
Broad Institute exome database (http://exac.broadinstitute
.org/, which gives anMITFp.E318K allele frequency of 0. 21%
[140MITFp.E318K alleles for 66732 total allele number]), the
riskof developingmelanoma inMITFp.E318Kcarrierswas4.7
(2.40-9.35; P < .01) and the risk of developing MPM was 6.3
(2.93-13.63;P < .01).Weassessed theassociationbetweenclini-
cal andphenotypic features and thepresence of p.E318K. The
presence of the variant was associated with a very high nevi
count (>200) inallpatientswithwild-typep16INK4A(8.4 [2.14-
33.19];P < .01)and inthosewithMPM(12.4 [2.58-59.7];P < .01).
We did not find any association with other phenotypical
characteristics, family history of pancreatic cancer (Table 1),
or clinicohistopathologic characteristicsof tumors (Table2and
eTable 1 in the Supplement).
Table 3 reports the detailed clinical, phenotypic, and
genetic characteristics of all patients with melanoma carry-
ing MITF p.E318K. Patient M0881-01, with 3 previous mela-
nomas, developed a fast-growing nodular melanoma that
had not been present in a visit 2 months earlier that
included total body photography. The patient detected a
Table 1. Melanoma Risk and Phenotypic Features According to the Presence ofMITF p.E318K
in PatientsWithWild-Type p16INK4A
Characteristic
No. (%)
OR (95% CI) P ValueMITF p.E318K WT
Melanoma Riska
All patients 9 (1.9) 453 (98.1) 3.3 (1.43-7.43) <.01
MPM 7 (2.6) 264 (97.4) 4.5 (1.83-11.01) <.01
Phenotypic Features
All MM patients
>200 Nevi 4 (44.4) 28 (8.7) 8.4 (2.14-33.19) <.01
Missing 0 130
Fair skin 6 (66.7) 207 (57.3) 1.49 (0.37-6.04) .74
Missing 0 92
Non-blue eyes 8 (88.9) 264 (78.3) 2.21 (0.27-17.98) .69
Missing 0 116
Dark hair 6 (66.7) 232 (68.6) 0.90 (0.22-3.72) >.99
Missing 0 115
MPM
>200 Nevi 4 (57.1) 19 (9.7) 12.4 (2.58-59.7) <.01
Missing 0 68
Fair skin 5 (71.4) 121 (58.5) 1.8 (0.34-9.37) .70
Missing 0 57
Non-blue eyes 6 (85.7) 140 (73.7) 2.1 (0.25-18.24) .68
Missing 0 74
Dark hair 5 (71.4) 126 (65.6) 1.3 (0.25-6.93) >.99
Missing 0 72
Familial history of pancreatic cancer
Presence 1 (11.1) 15 (4.29) 2.9 (0.34-24.49) .33
Missing 0 93
Abbreviations: MM,malignant
melanoma; MPM,multiple primary
melanoma; OR, odds ratio;
WT, wild-type.
a Data from 1659 French, 546 Italian,
and 499 Spanish cancer-free
controls were used. TheMITF
p.E318K frequency in the controls
was 0.6% (16 of 2704).
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fast-growing hypopigmented lesion on the elbow that arose
3 weeks before an urgent evaluation at our unit (Figure 1).
With dermoscopy, the lesion showed an unspecific pattern,
with asymmetry in the distribution of colors and structures,
the presence of blue-gray color, and milky-red areas with
some vessels. In confocal microscopy, the lesion showed
some bright, large, round cells in the upper epidermis
around a central ulceration; in the dermoepidermal junc-
tion, papilla were not well demarked and not visible in some
areas with dermal nests of noncohesive bright cells with
large nuclei, highly suggestive of melanoma. The lesion was
excised the same day with the final diagnosis of nodular
melanoma with Breslow thickness of 1.3 mm, ulceration,
5 mitoses/mm2, and epithelioid cells. Wide excision was
performed and sentinel lymph node biopsy identified 3
negative sentinel lymph nodes.
Patient M1340-01, in follow-up for recurrent lentigo ma-
ligna melanoma, had also developed a fast-growing mela-
noma, in this case amelanotic, that had not been present in a
visit 4 months earlier. Under dermoscopy, the lesion also
showed an unspecific pattern with remnants of pigmenta-
tion, the presence of doted and linear irregular vessels, and
short white streaks. The lesionwas excised and the diagnosis
wassuperficial-spreadingmelanoma inavertical growthphase
with a Breslow thickness of 1.65 mm, lack of ulceration,
3 mitoses/mm2, and fusocellular morphology. Wide excision
was performed, and sentinel lymph node biopsy identified
3 negative sentinel lymph nodes.
PatientM3879-01belongedtoa familywith2casesofmela-
noma; thus,weassessedwhether theotherpatient carried the
variant. In this case,MITFp.E318Kdidnotsegregatewithmela-
noma; however, the carrier was younger at the time of diag-
Table 2. Clinicohistopathologic Features According to the Presence ofMITF p.E318K
in PatientsWith p16INK4AWild-Type
Characteristic MITF p.E318K WT OR (95% CI) P Value
All Patients (N = 462)a
Melanoma subtype, No. (%)b
SSM 8 (100) 295 (86.3) NA .60
NM 1 (12.5) 35 (10.2) 1.25 (0.15-10.48) .58
LMM 1 (12.5) 42 (12.3) 1.02 (0.12-8.50) >.99
ALM 1 (12.5) 11 (3.2) 4.30 (0).49-38.02) .25
Other 0 6 (1.8) NA >.99
Missing 1 (11.1) 111 (24.5) NA
Melanoma location, No. (%)
Head or neck 2 (22.2) 54 (14.3) 1.71 (0.35-8.47) .62
Trunk 5 (55.6) 198 (52.4) 1.13 (0.30-4.30) >.99
Extremity 7 (77.8) 237 (62.7) 2.08 (0.43-10.16) .50
Other 0 3 (0.8) NA >.99
Missing 0 75 (16.6) NA
MPM (n = 271)
Melanoma subtype
SSM 7 (100) 197 (92.1) NA .66
NM 1 (14.3) 22 (10.3) 1.5 (0.17-12.64) .54
LMM 1 (14.3) 32 (15.0) 0.9 (0.11-8.14) >.99
ALM 1 (14.3) 7 (3.3) 4.9 (0.52-46.62) .23
Other 0 3 (1.4) NA >.99
Missing 0 51 (19.3) NA
Melanoma location
Head or neck 1 (14.3) 38 (16.7) 0.8 (0.10-7.12) >.99
Trunk 5 (71.4) 173 (75.9) 0.8 (0.15-4.21) >.99
Extremity 6 (85.7) 129 (56.6) 4.6 (0.54-38.87) .24
Other 0 2 (0.9) NA >.99
Missing 0 37 (14.0) NA
≥3 Primaries 2 (28.6) 51 (23.9) 1.2 (0.24-5.92) .83
Breslow thickness,
No. (median) [SD]c
All melanomas 12 (0.90) [1.54] 360 (0.76) [1.82] NA .43
First melanoma 5 (1.00) [2.26] 230 (0.89) [2.17] NA .33
Missing 1 119 NA
Age at diagnosis of first
melanoma, mean (SD), y [No.]
44.22 (16.60) [9] 46.83 (16.38) [406] NA
.64
Missing, No. 0 47 NA
Abbreviations: ALM, acral lentiginous
melanoma; LMM, lentigomalignant
melanoma; MPM,multiple primary
melanoma; NA, not applicable;
NM, nodular melanoma;
SSM, superficial spreadmelanoma;
WT, wild-type.
a There was a total of 462 patients.
The number indicates the total
number of primary melanomas
diagnosed with the subtype or
location indicated in each row,
within each group of patients (MITF
p.E318K carriers or patients with the
WTMITF).
bData on subtypes were determined
based on the number of patients
with at least 1 tumor of this subtype
or location. Data onmissing
information refers to the total
number of patients with missing
information.
c In situ melanomas were not
considered when calculating the
Breslowmedian thickness
(millimeters).
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nosis (30s vs 70s).We also detected 2healthy individuals car-
rying the variant in this family: M3879-03 and M3879-09
(phenotypic features of those 2 individuals are also recorded
inTable 3). Thenevi fromcarriers followed a reticular pattern
and were dark brown (Figure 2).
Discussion
In this study, we analyzed the prevalence ofMITF p.E318K in
Spanishpatientswithmelanoma.Toourknowledge, this is the
first study in which a set of individuals bearing mutations in
CDKN2Aaffectingp16INK4Awasalso tested forMITFp.E318K.
We detected a prevalence of 1.9% of the variant in all patients
withwild-type p16INK4A,whichwas higher in theMPMsub-
group (2.6%), and a similar prevalencewas found in the set of
patients with the p16INK4A mutation (2.9%). Previous
studies14-17,19 reported thatMITFp.E318K increases the risk of
developing melanoma (eTable 2 in the Supplement). We also
detected this association in our set of patients. In addition to
reporting increasedmelanomarisk,Yokoyamaandcolleagues15
stated that the presence of this variant was associated with a
high nevi count in an Australian and UK population. We also
found thatMITF p.E318K is associated with a very high nevi
count (>200nevi) in aMediterraneanpopulation. These find-
ings suggest thatMITFmaybe involved in nevogenesis. Twin
studies20-22have revealed evidence that the nevi count is ge-
neticallydetermined,withanadditivegenetic varianceof 36%
to84%, increasingwith age. Thenevi count is apolygenic trait
determinedbymultiple alleles.23-27 Thepresent studyand the
results in Australian and UK populations indicate that MITF
p.E318K should be included in the set of known genes
involved in this phenotypical trait.
Toourknowledge,onlyonestudy19hasdescribed thephe-
notypical features anddermoscopicpatternofnevi fromMITF
p.E318K carriers in Australian patients. The investigators
observed that these carriers hadpinkor light brownnevi, sug-
gesting that MITF p.E318K could modulate nevi pigmenta-
tion. In contrast, in our study, the nevi were dark brown, in-
dicating that other genesmay be involved in this feature. The
MC1R genemaymodulate the pigmentation of the nevi since
melanomas fromcarriersofRHCvariantsare lesspigmented.28
Otherwise, in the Australian study19 and ours, the dermo-
scopic pattern of nevi present in MITF p.E318K carriers was
predominantly reticular. These findings are suggestive of
photoinduced nevogenesis.29
Sturmandcolleagues19 noticedahigh incidenceof amela-
noticmelanomawithinMITFp.E318K carriers. One of our pa-
tients (M1340-01) also developed this type ofmelanoma. The
patient carried oneMC1R RHC variant: p.R151C. However, al-
though our findings support the hypothesis that a genetic in-
teraction between MC1R RHC and MITF p.E318K could in-
crease the risk of developing amelanotic melanomas, it has
been reported17 that the interaction of MITF and MC1R vari-
ants is not associated with melanoma pigmentation.
Ghiorzo and colleagues16 found an association between
MITFp.E318Kand thepresenceofnodularmelanomas.Wedid
notdetect a significant associationwithanyclinicohistopatho-
logic features, probably because the sample size lacked the
power todetect thesepossibleassociations.However,wenoted
2fast-growingmelanomas in2MITFp.E318Kcarrierswhowere
receivingdermatologic surveillanceowing to apreviousmela-
noma diagnosis. Dermatologic digital follow-up has been
demonstrated30,31 to be relevant for detecting melanomas at
early stageswith a low rate of excisions in patients at high risk
to develop melanoma. During 10 years of dermatologic sur-
veillance of patients at high-risk of melanoma in our mela-
noma unit (from January 1, 1999, to December 31, 2008), 98
newmelanomas were diagnosed in these patients; 54%were
in situ melanoma and 46%were invasive melanoma. Among
the invasivemelanomasdiagnosed,nonewasmore than1-mm
Breslow thickness and no melanomas behaved as fast-
Table 3. Clinical, Phenotypic, and Genetic Features of the SpanishMITF p.E318K Carriers
Identification,
Patient
No. of
Melanomas
Sex/Age of
Onset, y Hair/Eye Color Phototypea Nevi Count Other Tumors
CDKN2AMutations
MC1R Missense
Variantsbp16INK4A p14ARF
M0109-01 NA M/NA NA/NA NA NA NA p.D84Y p.R98L R142H
M0881-01 4 M/40s Brown/brown II >200 BCC No p.G32R I155T
M1340-01 2 M/60s Brown/blue II <50 BCC and RCC No No R151C and V92M
M1545-01 2 F/40s Blond/green II >200 BCC No No V60L
M1569-01 4 M/20s Blond/green II 100-200 No No No WT
M3824-01 2 F/70s Brown/brown II <50 No No No WT
M3879-01 2 F/30s Brown/brown III >200 No No No WT
M3879-03 0 F/NA Black/brown II >200 No No No V60L
M3879-09 0 F/NA Brown/brown II 100-200 No No No WT
M4182-01 2 M/20s Brown/brown III >200 No No No R160W
M4619-01 1 M/30s Blond/green II 100-200 No No No V92M
M4713-01 1 M/40s Brown/brown III 50-100 No No No V92M
M4999-01 1 F/40s Blond/green II >200 No p.A127S No R163Q
Abbreviations: BCC, cutaneous basal cell carcinoma; NA, not available; RCC, renal cell carcinoma; WT, wild-type.
a The phototype is indicated using the Fitzpatrick Scale.
bAll variants were detected in heterozygosis.
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growingmelanomas.31,32Until now inourmelanomaunit, the
only2fast-growingmelanomas identifiedbydermatologicdigi-
tal follow-up in individuals at high risk of melanoma were in
MITFp.E318Kcarriers.Fast-growingmelanomasaredefinedby
havingagrowth rateof greater than0.4mmpermonth; ingen-
eral, the melanoma growth rate is approximately 0.1 mm per
month,andslow-growingmelanomasusuallyhaveagrowthrate
of 0.01 mm per month.33 Furthermore, a high growth rate is
Figure 1. Melanoma
Clinical imageA Confocal images
Dermoscopic imageB
Histologic specimenE Close-up of histologic specimenF
C D
A fast-growingmelanoma developed
within 3 weeks and was the fourth to
occur in patient M0881-01. Clinical
picture of a 4-mm-diameter nodular
lesion located on the elbow (A);
dermoscopic image of the lesion
showing hypopigmentation,
asymmetry, unspecific pattern,
atypical vessels, and blue-whitish veil
(B). Under confocal microscopy, the
lesion shows an ulcerated central
area (C) with atypical nests in upper
dermis with bright roundish
nucleated cells in noncohesive nests
(D). Histopathologic examination
shows an ulcerated nodular
melanoma (hematoxylin-eosin,
original magnification ×2) (E) and
nests of atypical cells and presence of
mitosis (hematoxylin-eosin, original
magnification ×10) (F).
Figure 2. Nevi
The back of patient M3879-01 with 2
previous melanomas andmore than
200 nevi. Six dermoscopic images
show the predominant pattern,
reticulated dark brown.
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associated with a worse prognosis in melanoma; thus, strate-
gies for early detection of fast-growing melanomas are
necessary.34 Although further studies should address the role
ofMITFp.E318Kinfast-growingmelanoma, thecarriersofMITF
p.E318K should be encouraged to performmonthly total-body
self-examination of the skin and receive fast-track, urgent
dermatologic visits if any new lesion appears.
Genetic counseling is increasingly being offered to pa-
tientswith sporadicMPMor familialmelanomaand/or to their
healthy relatives.35 The genetic counseling inmelanoma is fo-
cused on the screening of high-penetrance genes such as
CDKN2A.AlthoughMITFp.E318K isamoderatemelanomarisk
allele, it also increases the risk of developing RCC and pan-
creatic cancer. In our set of carriers, we observed that 42.9%
(3 of 7) of the patients carryingMITF p.E318K developed cu-
taneousbasal cell carcinoma,which is similar topreviousdata
reported inwild-typeCDKN2AMPM.36We did not detect any
associationwithpancreatic cancer,probablyowing to thesmall
number of carriers in the study. Reinforcing their predisposi-
tion to developRCC, 14.3% (1 of 7) carriers haddeveloped this
kind of tumor. Thus, if genetic counseling included MITF
p.E318Kgenetic testing, individuals carrying theMITFp.E318K
variant could benefit from being included both in melanoma
andRCCprevention/surveillanceprograms. Furthermore, the
detection ofMITFp.E318Kmay identify patients at risk of de-
veloping fast-growingmelanomas. We have observed a simi-
larprevalenceofMITFp.E318K incaseswithgermlineCDKN2A
mutationsas inpatientswithwild-type.However, further stud-
ies should be performed to assess the role ofMITF p.E318K as
a possiblemodulator of the effect ofCDKN2Amutations. This
result suggests that individuals with a mutation in CDKN2A
might alsobe included inMITFp.E318K screening as the iden-
tification of this variant allows for better characterization of
the risk in the family and to adapt the cancer surveillance
programs accordingly.
Patients withMITF p.E318K should be encouraged to fol-
lowmelanoma prevention programs, which include sun pro-
tection strategies, monthly self-examination of the skin, and
dermatologic surveillance.BecauseMITFp.E318Khasbeenas-
sociatedwithRCC,14 theuseof renal ultrasonographyas a safe
and low-cost screening technique todetect thepresenceofkid-
ney tumors should be considered. Future studies should ex-
plore the cost-efficacy and acceptance of this screening tech-
nique in MITF p.E318K carriers. It would be important to
recommend that carriers avoid smoking and control their
weight since smoking and obesity are important risk factors
for both RCC and pancreatic cancer.37,38 Moreover, detection
ofMITFp.E318K in apatient leads to thepossibility of extend-
inggenetic testing toother relatives, andpositive cases should
be encouraged to follow the same preventive measures.
Conclusions
Basedon the results of this study,MITF (andMC1R) should be
added to CDKN2A/CDK4 genetic testing based on published
international recommendations for countries with low and
high sun exposure.39 Genotyping forMITF (andMC1R) could
be added to predictive testing for all relatives in CDKN2A-
positive families.
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